Trials / Terminated
TerminatedNCT04930055
Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,206 (actual)
- Sponsor
- Indiana University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The goals of this study are to assess initial or booster vaccine performance (safety and efficacy) and to collect serum and peripheral blood mononuclear cells (PBMCs) pre and post-vaccination to assess immune and other response parameters following immunization in cancer patients receiving either the Pfizer (BTN162b2), Moderna (mRNA-1273), or the Janssen (Ad26.COV2.S) vaccines.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | COVID-19 Vaccination | Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care |
Timeline
- Start date
- 2021-06-30
- Primary completion
- 2021-11-01
- Completion
- 2022-03-08
- First posted
- 2021-06-18
- Last updated
- 2023-05-19
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04930055. Inclusion in this directory is not an endorsement.